MedTrace Logo

AI-EMERGE: Development and Validation of a Multi-analyte, Blood-based Colorectal Cancer Screening Test

NCT03688906 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3275

Last updated 2022-03-02

No results posted yet for this study

Summary

Freenome is using a type of artificial intelligence, called machine learning, to identify patterns of cell-free biomarkers in blood to detect cancer early. The purpose of this study is to develop and validate a blood-based assay to detect colorectal cancer by collecting blood and stool samples from healthy patients undergoing routine screening colonoscopy and from patients recently diagnosed with colorectal cancer or advanced adenomas.

Conditions

  • Colo-rectal Cancer
  • Cancer Colon
  • Cancer, Rectum
  • Neoplasms,Colorectal
  • Polyps
  • Polyp of Colon
  • Adenoma
  • Adenoma Colon

Sponsors & Collaborators

  • Freenome Holdings Inc.

    lead INDUSTRY

Principal Investigators

  • Girish Putcha, M.D., Ph.D · Freenome Holdings Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-12
Primary Completion
2019-11-25
Completion
2019-11-25

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03688906 on ClinicalTrials.gov